NVS Q4 2025 Earnings Call Summary

Novartis Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Sales Growth: Novartis reported an 8% increase in sales for the full year 2025, achieving $61.4 billion.
Core Operating Income (Core OpInc): Increased by 14% to $21.9 billion, with a core margin of 40.1%, achieved two years ahead of schedule.
Quarterly Performance: Q4 sales declined by 1%, while Core OpInc grew by 1%. Adjusted for one-time R&D adjustments, underlying Q4 sales growth would have been +3%.
Core EPS: Rose 17% to $8.98 for the full year; Q4 Core EPS was $2.03, up 2%.
Free Cash Flow: Reached an all-time high of $17.6 billion, up 8% year-over-year.

2. Strategic Updates and Business Highlights

Pipeline Developments:
- Remibrutinib: Positive Phase III results led to submission for chronic inducible urticaria.
- Pelabresib: Data from the Phase III MANIFEST program showed promising results, with plans for regulatory submissions in 2026.
- Kisqali: Grew 57% to $4.8 billion, with strong volume growth and a peak sales outlook of $10 billion.
- Kesimpta: Increased by 36% to $4.4 billion, with a focus on expanding B-cell therapies.
- Pluvicto: Achieved $2 billion in sales, with significant growth expected from upcoming launches in Japan and China.
Acquisitions and Investments: Over $10 billion invested in R&D, with four acquisitions and ten licensing deals announced.

3. Forward Guidance and Outlook

2026 Expectations:
- Sales growth projected to be low single digits, with Core OpInc expected to decline low single digits due to Avidity deal-related dilution.
- Anticipated first half of 2026 to be challenging due to U.S. generic entries impacting sales, particularly for Entresto, Promacta, and Tasigna.
- Long-term growth forecast remains strong with a 5-6% CAGR expected through 2030.

4. Bad News, Challenges, or Points of Concern

Generic Competition: The entry of U.S. generics for key products like Entresto is expected to impact sales in 2026.
Market Dynamics: Concerns about the competitive landscape in multiple therapeutic areas, particularly with oral SERDs in oncology and other emerging therapies.
Regulatory Risks: Potential delays or challenges in ongoing clinical trials, particularly for pelacarsen and zigakibart, could affect future growth.

5. Notable Q&A Insights

Remibrutinib: Management expressed confidence in the safety profile and market potential, despite competition concerns.
Pelacarsen: Acknowledged the lower-than-expected event rates in the HORIZON trial, with management remaining optimistic about the drug's commercial prospects even with a potential lower efficacy than initially targeted.
Kisqali and Competitive Landscape: Management is focused on lifecycle management strategies to extend the brand's market presence beyond its patent expiry.
Food Allergy Opportunity: Novartis is optimistic about the potential for its food allergy treatments, particularly with upcoming Phase II data expected to support further development.

Overall, Novartis demonstrated strong financial performance in 2025, with a robust pipeline and strategic initiatives aimed at sustaining growth despite facing significant challenges from generic competition and evolving market dynamics.

NVS — Novartis AG